Germany-based Boehringer Ingelheim is spending $80 million to construct an avian vaccine plant in Lyon, France.
The factory, set to open in spring 2020 on the company’s Lyon Porte-des-Alpes site, will serve the world market with the exception of the United States.
“As poultry consumption continues to rise around the world, there is an increasing demand for avian vaccines,” said Erick Lelouche, president of Boehringer Ingelheim Animal Health France.
“We had to do some forward planning and find additional production capacity.”
The 61,000-square-foot plant will operate two lines and create 42 jobs, the company reported April 11.
The news came 15 months after Boehringer Ingelheim’s acquisition of Merial Ltd.
“An investment such as this confirms the commitment made by Boehringer Ingelheim … to put France, and Lyon in particular, at the heart of its growth strategy in the animal health market,” Lelouche said.